Genetic Markers for Aggressive Head and Neck Cancer Identified
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Genetic Markers for Aggressive Head and Neck Cancer Identified

BRONX, NY -- March 18, 2009 -- Researchers have identified genetic markers that signal poor outcomes for patients with head and neck cancer, according to a study published in the March issue of the American Journal of Pathology.

The findings could one day lead to a genetic test that could help select or predict successful treatment options for patients with this type of cancer.

Richard Smith, MD, Albert Einstein College of Medicine at Yeshiva University, and Montefiore Medical Center, Bronx, New York, and colleagues analysed samples from 104 patients with head and neck cancer who were treated at Montefiore Medical Center.

The patients were treated and followed over 5 years. At the time of cancer diagnosis and before any therapy, researchers removed samples tumour tissue from patients, as well as normal tissue adjacent to their tumour, and measured microRNA levels in the 2 types of tissue.

Patients who fared worst had the lowest levels of miR-205 and let-7d in their tumour tissue. Specifically, these patients were 4 times more likely to have an earlier metastasis or local-regional recurrence of their cancer than patients with higher levels of miR-205 and let-7.

"A biologic marker identifying aggressive tumours would allow us to direct therapy more appropriately, minimising over or under-treatment," said Dr. Smith.

"Our next steps are to confirm these results in a new patient population and to find additional markers that would allow us to develop a reproducible and accurate prognostic test," said senior author Nicolas Schlecht, PhD, Albert Einstein College of Medicine.

SOURCE: Albert Einstein College of Medicine of Yeshiva University

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities